Eli Lilly stock climbs near 2%: China drug approval and GLP-1 pill race in focus
Eli Lilly and Company climbed almost 2% Thursday, pushing its rebound further as the company reported new regulatory progress for mirikizumab in China—a drug aimed at inflammatory bowel disease. By late morning, shares traded at $1,033.23, up 1.8%. The Health Care Select Sector SPDR Fund posted modest gains. Novo Nordisk’s U.S. shares, however, slipped.
